HLA Markers for Poor Prognosis in Systemic Sclerosis Brazilian Patients

Table 2

Frequency of class I HLA alleles in pulmonary fibrosis (PF) and pulmonary arterial hypertension (PAH).

HLA	PF			PAH
	+; 𝑁 (%)	−; 𝑁 (%)	𝑃	+; 𝑁 (%)	−; 𝑁 (%)	𝑃
	61	80		19	122
A*01	13 (21.3)	18 (22.5)	0.866	4 (2.0)	27 (22.1)	1
A*02	24 (39.3)	40 (50.0)	0.208	7 (36.8)	57 (46.7)	0.421
A*03	12 (19.6)	24 (30.0)	0.163	5 (26.3)	31 (25.4)	1
A*33	5 (8.2)	5 (6.2)	0.746	1 (5.3)	9 (7.4)	1
A*23	6 (9.8)	6 (7.5)	0.622	2 (10.6)	10 (8.2)	0.665
A*11	7 (11.5)	5 (6.2)	0.271	3 (15.8)	9 (7.4)	0.207
A*29	6 (9.8)	8 (10.0)	0.974	2 (10.6)	12 (9.8)	1
A*30	9 (14.7)	3 (3.7)	0.020	3 (15.8)	9 (7.4)	0.207
A*24	9 (14.7)	12 (15.0)	0.968	1 (5.3)	20 (16.4)	0.307
A*68	7 (11.5)	9 (11.2)	0.967	0 (0)	16 (13.1)	0.129
B*15	9 (14.7)	8 8 (10.0)	0.390	1 (5.3)	16 (13.1)	0.469
B*07	6 (9.8)	13 (16.2)	0.269	3 (15.8)	16 (13.1)	0.722
B*44	9 (14.7)	15 (18.7)	0.532	2 (10.6)	22 (18.0)	0.530
B*18	12 (19.6)	13 (16.2)	0.598	5 (26.3)	20 (16.4)	0.333
B*35	13 (21.3)	18 (22.5)	0.866	8 (42.1)	23 (18.8)	0.035
B*39	5 (8.2)	9 (11.2)	0.548	2 (10.6)	12 (9.8)	1
B*51	7 (11.5)	7 (8.7)	0.592	4 (21.0)	10 (8.2)	0.098
B*08	8 (13.1)	6 (7.5)	0.269	2 (10.6)	12 (9.8)	1
B*14	6 (9.8)	10 (12.5)	0.621	3 (15.8)	13 (10.6)	0.454
C*03	8 (13.1)	14 (17.5)	0.477	0 (0)	22 (18.0)	0.044
C*06	14 (22.9)	18 (22.5)	0.950	4 (21.0)	28 (22.9)	1
C*07	28 (46.0)	33 (41.3)	0.581	10 (52.6)	51 (41.8)	0.376
C*04	19 (31.1)	22 (27.5)	0.637	10 (52.6)	31 (25.4)	0.015
C*05	4 (6.6)	11 (13.7)	0.170	3 (15.8)	12 (9.8)	0.428
C*12	7 (11.5)	12 (15.0)	0.544	1 (5.3)	18 (14.7)	0.470
C*08	5 (8.2)	11 (13.7)	0.303	3 (15.8)	13 (10.6)	0.454
C*02	4 (6.6)	10 (12.5)	0.242	1 (5.3)	13 (10.6)	0.693